"
Team:Macquarie Australia/Outreach/Law
From 2014.igem.org
| Line 27: | Line 27: | ||
Australian legal scholarship has discussed synthetic biology, in particular, whether genes are patentable, for almost a decade. The U.S. Myriad decision ruled that genes are not patentable in the US, as the isolated product's factor of interest was the code of the base pairs, an entirely natural element. This posed a challenge to Australian legal scholars; Australia allowed domestic patenting of genes on the basis that isolated genes are chemically distinct to that found in DNA.</p> | Australian legal scholarship has discussed synthetic biology, in particular, whether genes are patentable, for almost a decade. The U.S. Myriad decision ruled that genes are not patentable in the US, as the isolated product's factor of interest was the code of the base pairs, an entirely natural element. This posed a challenge to Australian legal scholars; Australia allowed domestic patenting of genes on the basis that isolated genes are chemically distinct to that found in DNA.</p> | ||
<p> | <p> | ||
| - | In July 2014, the D'Arcy case appealed this issue to the High Court, testing the Myriad reasoning in Australian courts. The High Court upheld the Australian reasoning over the US reasoning, on the basis of Australian statutory wording's emphasis on 'artificial', in contrast to the US emphasis on ' | + | In July 2014, the D'Arcy case appealed this issue to the High Court, testing the Myriad reasoning in Australian courts. The High Court upheld the Australian reasoning over the US reasoning, on the basis of Australian statutory wording's emphasis on 'artificial', in contrast to the US emphasis on 'natural'. The Macquarie University iGEM team therefore has identified the need to review and provide a summary of Australian patent law in light of the new authority on the subject. |
<br/> | <br/> | ||
<div id="pdfList"> | <div id="pdfList"> | ||
Revision as of 04:43, 15 October 2014
Synthetic Biology in Australian Law
Australian legal scholarship has discussed synthetic biology, in particular, whether genes are patentable, for almost a decade. The U.S. Myriad decision ruled that genes are not patentable in the US, as the isolated product's factor of interest was the code of the base pairs, an entirely natural element. This posed a challenge to Australian legal scholars; Australia allowed domestic patenting of genes on the basis that isolated genes are chemically distinct to that found in DNA.
In July 2014, the D'Arcy case appealed this issue to the High Court, testing the Myriad reasoning in Australian courts. The High Court upheld the Australian reasoning over the US reasoning, on the basis of Australian statutory wording's emphasis on 'artificial', in contrast to the US emphasis on 'natural'. The Macquarie University iGEM team therefore has identified the need to review and provide a summary of Australian patent law in light of the new authority on the subject.
The Macquarie iGEM team urges the Australian Parliament to extend the exemption to patent regarding genes to commercial use of human genes, to ensure the best medical care is accessible to all Australians at an affordable cost.
